alpha 1 Antitrypsin (9C7) Monoclonal Antibody

$Lane 1: human spleen muscle lysates; Probed with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: human spleen muscle lysates; Probed with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human liver tissue incubated with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human liver tissue incubated with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with alpha 1 Antitrypsin (9C7) Monoclonal Antibody (bsm-52866R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Lane 1: Human Plasma probed with AACT Monoclonal Antibody, Unconjugated (bsm-52866R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Human Plasma probed with AACT Monoclonal Antibody, Unconjugated (bsm-52866R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
IHC-P
IF(ICC)
IHC

Reactivity

Human

Overview
Catalog #	bsm-52866R
Product Name	alpha 1 Antitrypsin (9C7) Monoclonal Antibody
Applications	WB, IHC-P, IF(ICC), IHC
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Full length protein
Clonality	Monoclonal
Clone #	9C7
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	5265
Swiss Prot	P01009
Synonyms	Alpha-1 protease inhibitor, Alpha-1-antiproteinase, Serpin A1, SERPINA1
Background	Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC